Lexicon to Present Phase 2 Results for LX1031 at GASTRO 2009

THE WOODLANDS, Texas -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will present top-line data from its Phase 2 clinical study with LX1031 in patients with non-constipating irritable bowel syndrome (IBS) at GASTRO 2009 in London. Results from the study, which showed a significant improvement in IBS symptoms, will be presented by Dr. Philip M. Brown, Lexicon's Senior V.P. of Clinical Development, on November 25, 2009 at 2:30 p.m. local time at the session entitled, "Therapeutic insights in functional digestive disorders."

The GASTRO 2009 meeting is a joint world conference in the area of gastroenterology. This meeting will bring together the world's leading organizations - the United European Gastroenterology Federation (UEGF), World Gastroenterology Organization (WGO), World Organization of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG) - for one of the biggest congresses in this area of medicine with more than 12,000 scientists from around the world expected to attend.

A summary of the GASTRO 2009 presentation (with audio) will be available on Lexicon's Web site at on November 25, 2009.